Literature DB >> 31153882

Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial.

Yong Lv1, Zhiping Yang1, Lei Liu1, Kai Li1, Chuangye He1, Zhengyu Wang1, Wei Bai1, Wengang Guo1, Tianlei Yu1, Xulong Yuan1, Hongbo Zhang2, Huahong Xie2, Liping Yao2, Jianhong Wang3, Tao Li3, Qiuhe Wang1, Hui Chen1, Enxin Wang1, Dongdong Xia1, Bohan Luo1, Xiaomei Li1, Jie Yuan1, Na Han1, Ying Zhu1, Jing Niu1, Hongwei Cai4, Jielai Xia5, Zhanxin Yin1, Kaichun Wu6, Daiming Fan6, Guohong Han7.   

Abstract

BACKGROUND: The survival benefit of early placement of transjugular intrahepatic portosystemic shunts (TIPS) in patients with cirrhosis and acute variceal bleeding is controversial. We aimed to assess whether early TIPS improves survival in patients with advanced cirrhosis and acute variceal bleeding.
METHODS: We did an investigator-initiated, open-label, randomised controlled trial at an academic hospital in China. Consecutive patients with advanced cirrhosis (Child-Pugh class B or C) and acute variceal bleeding who had been treated with vasoactive drugs plus endoscopic therapy were randomly assigned (2:1) to receive either early TIPS (done within 72 h after initial endoscopy [early TIPS group]) or standard treatment (vasoactive drugs continued to day 5, followed by propranolol plus endoscopic band ligation for the prevention of rebleeding, with TIPS as rescue therapy when needed [control group]). Randomisation was done by web-based randomisation system using a Pocock and Simon's minimisation method with Child-Pugh class (B vs C) and presence or absence of active bleeding as adjustment factors. The primary outcome was transplantation-free survival, analysed in the intention-to-treat population, excluding individuals subsequently found to be ineligible for enrolment. This study is registered with ClinicalTrials.gov, number NCT01370161, and is completed.
FINDINGS: From June 26, 2011, to Sept 30, 2017, 373 patients were screened and 132 patients were randomly assigned to the early TIPS group (n=86) or to the control group (n=46). After exclusion of three individuals subsequently found to be ineligible for enrolment (two patients in the early TIPS group with non-cirrhotic portal hypertension or hepatocellular carcinoma, and one patient in the control group due to non-cirrhotic portal hypertension), 84 patients in the early TIPS group and 45 patients in the control group were included in the intention-to-treat population. 15 (18%) patients in the early TIPS group and 15 (33%) in the control group died; two (2%) patients in the early TIPS group and one (2%) in the control group underwent liver transplantation. Transplantation-free survival was higher in the early TIPS group than in the control group (hazard ratio 0·50, 95% CI 0·25-0·98; p=0·04). Transplantation-free survival at 6 weeks was 99% (95% CI 97-100) in the early TIPS group compared with 84% (75-96; absolute risk difference 15% [95% CI 5-48]; p=0·02) and at 1 year was 86% (79-94) in the early TIPS group versus 73% (62-88) in the control group (absolute risk difference 13% [95% CI 2-28]; p=0·046). There were no significant differences between the two groups in the incidence of hepatic hydrothorax (two [2%] of 84 patients in the early TIPS group vs one [2%] of 45 in the control group; p=0·96), spontaneous bacterial peritonitis (one [1%] vs three [7%]; p=0·12), hepatic encephalopathy (29 [35%] vs 16 [36%]; p=1·00), hepatorenal syndrome (four [5%] vs six [13%]; p=0·10), and hepatocellular carcinoma (four [5%] vs one [2%]; p=0·68). There was no significant difference in the number of patients who experienced other serious adverse events (ten [12%] vs 11 [24%]; p=0·07) or non-serious adverse events (21 [25%] vs 19 [42%]; p=0·05) between groups.
INTERPRETATION: Early TIPS with covered stents improved transplantation-free survival in selected patients with advanced cirrhosis and acute variceal bleeding and should therefore be preferred to the current standard of care. FUNDING: National Natural Science Foundation of China, National Key Technology R&D Program, Optimized Overall Project of Shaanxi Province, Boost Program of Xijing Hospital.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31153882     DOI: 10.1016/S2468-1253(19)30090-1

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  30 in total

1.  Twitter debate: controversies in the management of portal hypertension.

Authors:  William Chung; James Maurice; David Patch
Journal:  Frontline Gastroenterol       Date:  2020-01-30

Review 2.  Emergent Transjugular Intrahepatic Portosystemic Shunt Creation in Acute Variceal Bleeding.

Authors:  Mithil B Pandhi; Andrew J Kuei; Andrew J Lipnik; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2020-03-04       Impact factor: 1.513

3.  Early transjugular intrahepatic portosystemic shunt for acute variceal bleeding: a systematic review and meta-analysis.

Authors:  Guang-Peng Zhou; Yi-Zhou Jiang; Li-Ying Sun; Zhi-Jun Zhu
Journal:  Eur Radiol       Date:  2021-01-06       Impact factor: 5.315

4.  Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis.

Authors:  Theresa Bucsics; Katharina Lampichler; Constantin Vierziger; Maria Schoder; Florian Wolf; David Bauer; Benedikt Simbrunner; Lukas Hartl; Mathias Jachs; Bernhard Scheiner; Michael Trauner; Thomas Gruenberger; Franz Karnel; Mattias Mandorfer; Thomas Reiberger
Journal:  Dig Dis Sci       Date:  2022-03-17       Impact factor: 3.199

5.  Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC).

Authors:  Sanchit Sharma; Samagra Agarwal; Anoop Saraya; Shiv Kumar Sarin; Ashok Choudhury; Mamun Al Mahtab; Mohd Shahinul Alam; Sanjiv Saigal; Dong Joon Kim; C E Eapen; Ashish Goel; Qin Ning; Harshad Devarbhavi; Virendra Singh; Akash Shukla; Saeed Hamid; Jinhua Hu; Soek-Siam Tan; Anil Arora; Manoj Kumar Sahu; Mohd Rela; Dinesh Jothimani; P N Rao; Anand Kulkarni; Hashmik Ghaznian; Guan Huei Lee; Duan Zhongping; Ajit Sood; Omesh Goyal; Laurentius A Lesmana; Rinaldi C Lesmana; Sombat Treeprasertsuk; Nan Yuemin; Samir Shah; Han Tao; V M Dayal; Xin Shaojie; Fazal Karim; Zaigham Abbas; Jose D Sollano; Kemal Fariz Kalista; Ananta Shreshtha; Diana Payawal; Masao Omata
Journal:  Hepatol Int       Date:  2022-07-18       Impact factor: 9.029

Review 6.  Overview of Complications in Cirrhosis.

Authors:  Madhumita Premkumar; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2022-05-14

7.  Single-Centre Retrospective Training Cohort Using Artificial Intelligence for Prognostic Prediction of Encephalopathy, Mortality, and Liver Dysfunction after Early TIPS Creation.

Authors:  Bin-Yan Zhong; Wan-Sheng Wang; Jian Shen; Hang Du; Shuai Zhang; Wan-Ci Li; Yu Yin; Jun Yang; Cai-Fang Ni; Xiao-Li Zhu
Journal:  Cardiovasc Intervent Radiol       Date:  2021-07-08       Impact factor: 2.740

Review 8.  Updated strategies in the management of acute variceal haemorrhage.

Authors:  Jerome Edelson; Jessica E Basso; Don C Rockey
Journal:  Curr Opin Gastroenterol       Date:  2021-05-01       Impact factor: 3.287

Review 9.  Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020.

Authors:  Adelina Horhat; Christophe Bureau; Dominique Thabut; Marika Rudler
Journal:  United European Gastroenterol J       Date:  2021-02-23       Impact factor: 4.623

Review 10.  North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.

Authors:  Justin R Boike; Bartley G Thornburg; Sumeet K Asrani; Michael B Fallon; Brett E Fortune; Manhal J Izzy; Elizabeth C Verna; Juan G Abraldes; Andrew S Allegretti; Jasmohan S Bajaj; Scott W Biggins; Michael D Darcy; Maryjane A Farr; Khashayar Farsad; Guadalupe Garcia-Tsao; Shelley A Hall; Caroline C Jadlowiec; Michael J Krowka; Jeanne Laberge; Edward W Lee; David C Mulligan; Mitra K Nadim; Patrick G Northup; Riad Salem; Joseph J Shatzel; Cathryn J Shaw; Douglas A Simonetto; Jonathan Susman; K Pallav Kolli; Lisa B VanWagner
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-15       Impact factor: 13.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.